首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1624385

全球幹細胞治療市場規模：按來源、按應用、按最終用戶、按地區、範圍和預測

Global Stem Cell Therapy Market Size By Source, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2024年08月19日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

幹細胞治療市場規模及預測

2023年幹細胞治療市場規模為118億美元，預計2030年將達到314.1億美元，2024-2030年預測期間複合年增長率為13.95%。幹細胞治療市場包括使用幹細胞治療各種疾病和病症。幹細胞具有分化成各種細胞類型的獨特能力，在再生醫學領域具有廣闊的前景，在治療心血管疾病、神經退化性疾病、肌肉骨骼損傷、自體免疫疾病等方面具有潛在的應用前景。可能性已被廣泛研究。幹細胞療法涉及幹細胞的移植和操作，以促進組織修復、再生和功能恢復，為解決未滿足的醫療需求提供創新的解決方案。

推動全球幹細胞治療市場的因素

幹細胞治療的市場推動因素受到多種因素的影響。

慢性病盛行率：

隨著癌症、心臟病和神經系統疾病等慢性疾病變得越來越普遍，對幹細胞治療的需求也增加。

幹細胞研究進展：

誘導多能幹細胞（iPS細胞）和基因編輯方法等幹細胞研究和開發的進展正在進一步擴大幹細胞治療的應用和有效性。

人口老化：

隨著世界人口老化，與年齡相關的疾病變得更加普遍，增加了對再生治療（例如幹細胞療法）治療退化性疾病的需求。

擴大再生醫學投資：

製藥公司、生技公司和研究機構對再生醫學和幹細胞治療的投資增加，正在刺激新療法的發現和商業化。

增加患者知識和需求：

全球對幹細胞療法的接受度是由於患者對該療法的潛在益處的瞭解不斷增加，以及患者對客製化再生醫學的需求不斷增加。

監管支持和批准：

許多國家已採用清晰可靠的幹細胞治療法規和指南，為產品研究和商業化開闢新途徑，有助於擴大市場。

創新：

透過幹細胞分離、培養、分化和遞送技術的創新，提高了幹細胞療法的安全性、有效性和可擴展性，促進了幹細胞療法在臨床中的使用。

夥伴關係與協作：

研究機構、學術機構和商業領袖可以透過交流專業知識和資源進行合作，加速幹細胞藥物的開發。

擴大細胞庫投資：

增加對幹細胞庫和儲存設施的投資以保存臍帶血和其他幹細胞來源，增加了可用於治療目的的細胞來源的可用性。

個人化醫療的可能性：

幹細胞療法可以為每位患者量身訂做細胞療法和組織工程治療。這為未滿足的醫療需求提供了新的治療機會。

限制全球幹細胞治療市場的因素

幹細胞治療市場存在一些抑制因素和課題。

道德/法律問題：

幹細胞治療領域的研究和開發工作受到圍繞胚胎幹細胞使用的倫理爭論以及某些地區的監管和法律限制的阻礙。

昂貴的治療費用：

分離、培養、操作和管理細胞的高成本阻礙了患者獲得幹細胞治療並負擔得起。這也限制了幹細胞治療產業的擴張。

有限的臨床證據：

儘管臨床前研究顯示出有希望的結果，但缺乏有關幹細胞療法的安全性、有效性和結果的可靠臨床證據和長期數據，阻礙了其廣泛使用和接受。

不良事件的風險

鑑於對幹細胞治療可能產生的副作用（例如腫瘤發展、免疫原性和遺傳異常）的擔憂，認真的安全性評估和患者追蹤非常重要。

幹細胞生物學的複雜性：

幹細胞生物學的複雜性，包括免疫相容性、分化過程和細胞命運決定，使得治療程序標準化和獲得一致的結果變得困難。

可擴展性和標準化有限：

幹細胞生產、品質控制和製造程序的可擴展性和標準化問題阻礙了幹細胞療法的商業化和廣泛採用。

免疫排斥反應：

需要開發免疫調節技術和患者特異性療法來解決對免疫排斥和移植物抗宿主反應的擔憂，這些反應限制了異體幹細胞療法的應用。

監管障礙：

嚴格的監管要求、漫長的審批流程以及因國家而異的幹細胞療法不斷變化的監管環境阻礙了市場進入和商業化。

保險範圍問題：

由於有限的保險覆蓋範圍和支付法規，尋求幹細胞治療的患者和醫療保健提供者在許多醫療保健系統中面臨障礙，這阻礙了市場的成長。

公眾的看法和懷疑：

聳人聽聞的報告和未經證實的說法助長了對幹細胞治療的誤解、懷疑和錯誤訊息，阻礙了患者和醫療保健提供者對幹細胞治療的接受和採用。

Novartis AG（Switzerland）
Johnson & Johnson（USA）
Roche Holding AG（Switzerland）
Celgene Corporation（USA）
Gilead Sciences, Inc.（USA）
Mesoblast Limited（Australia）
Osiris Therapeutics, Inc.（USA）
Bluebird bio, Inc.（USA）
Editas Medicine, Inc.（USA）
Spark Therapeutics, Inc.（USA）

第11章市場前景與機遇

新興技術
未來市場趨勢
投資機會

第12章附錄

縮寫表
來源和參考文獻

簡介目錄

Product Code: 24113

Stem Cell Therapy Market Size And Forecast

Stem Cell Therapy Market size was valued at USD 11.8 Billion in 2023 and is projected to reach USD 31.41 Billion by 2030 , growing at a CAGR of 13.95% during the forecast period 2024-2030. The Stem Cell Therapy Market encompasses the utilization of stem cells for the treatment of various diseases and medical conditions. Stem cells, characterized by their unique ability to differentiate into different cell types, hold immense promise in regenerative medicine and have been studied extensively for their potential in treating conditions such as cardiovascular diseases, neurodegenerative disorders, musculoskeletal injuries, and autoimmune diseases. Stem cell therapy involves the transplantation or manipulation of stem cells to promote tissue repair, regeneration, and restoration of function, offering innovative solutions for addressing unmet medical needs.

Global Stem Cell Therapy Market Drivers

The market drivers for the Stem Cell Therapy Market can be influenced by various factors. These may include:

Growing Prevalence of Chronic Conditions:

As chronic illnesses like cancer, heart disease, and neurological problems become more common, there is a greater need for stem cell therapies as possible forms of treatment.

Developments in Stem Cell Research:

The therapeutic uses and effectiveness of stem cell therapies are being broadened by the ongoing developments in stem cell research, which include the creation of induced pluripotent stem cells (iPSCs) and gene editing methods.

Aging Population:

As the world's population ages, age-related illnesses and ailments are more common, which increases the need for regenerative therapies such stem cell treatments to treat degenerative disorders.

Growing Investments in Regenerative Medicine:

The discovery and commercialization of novel treatment options are fueled by the increasing investments made in regenerative medicine and stem cell-based therapies by pharmaceutical corporations, biotechnology businesses, and research institutes.

Growing Patient Knowledge and Desire:

The acceptance of stem cell therapies worldwide is aided by rising patient knowledge of the potential advantages of the treatment, as well as a growing desire for customized and regenerative approaches.

Regulatory Support and Approvals:

Clear, credible regulations and favorable guidelines for stem cell therapies across a number of nations drive market expansion by opening up new avenues for product research and commercialization.

Technological Innovations:

The safety, effectiveness, and scalability of stem cell therapies are improved by technological breakthroughs in stem cell isolation, culture, differentiation, and delivery techniques, which promotes the use of stem cell therapies in clinical practice.

Partnerships and Collaborations:

Research organizations, academic institutions, and business leaders can work together to speed the development of stem cell-based medicines by exchanging expertise and resources.

Growing Investments in Cell Banking:

The availability of viable cell sources for therapeutic use is supported by growing investments in stem cell banking and storage facilities for preserving umbilical cord blood and other stem cell sources.

Potential for Personalized Medicine:

Personalized cell-based therapies and tissue engineering solutions, which can be customized to meet the specific demands of each patient, are made possible by stem cell therapies. This presents exciting new opportunities for treating unmet medical needs.

Global Stem Cell Therapy Market Restraints

Several factors can act as restraints or challenges for the Stem Cell Therapy Market. These may include:

Ethical and Legal Issues:

Research and development efforts in the field of stem cell treatment are hampered by ethical debates around the use of embryonic stem cells as well as regulatory and legal limitations in some areas.

High Treatment Costs:

Patients' access to and affordability of stem cell therapy procedures are hampered by the high costs of cell isolation, culture, manipulation, and administration. This also restricts the expansion of the industry.

Limited Clinical Evidence:

Although preclinical results are encouraging, there is currently a dearth of solid clinical evidence and long-term data regarding the safety, effectiveness, and results of stem cell therapies, which is preventing their broad use and acceptance.

Risk of Adverse Events:

Serious safety evaluations and patient follow-up are important in light of worries regarding the possible side effects of stem cell treatments, including tumor development, immunogenicity, and genetic abnormalities.

Complexity of Stem Cell Biology:

It can be difficult to standardize treatment procedures and produce consistent results due to the complexity of stem cell biology, which includes problems with immunological compatibility, differentiation processes, and cell fate determination.

Limited Scalability and Standardization:

Commercialization and broad adoption of stem cell therapies are hampered by issues with the scalability and standardization of stem cell production, quality control, and manufacturing procedures.

Immunological Rejection:

Immunomodulatory techniques and patient-specific methods must be developed in order to address concerns regarding immunological rejection and graft-versus-host reactions, which restrict the application of allogeneic stem cell therapies.

Regulatory Obstacles:

Obstacles to market entry and commercialization for industry players include strict regulatory requirements, protracted approval processes, and changing regulatory environments for stem cell therapies in different countries.

Insurance Coverage Issues:

Patients and providers trying to access stem cell therapies face obstacles due to limited insurance coverage and payment regulations in many healthcare systems, which hinders market growth.

Public Perception and Skepticism:

Patients' and healthcare professionals' acceptance and adoption of stem cell therapy are hampered by widespread misperceptions, skepticism, and disinformation regarding the treatment, which are driven by sensationalized media coverage and unverified claims.

Global Stem Cell Therapy Market Segmentation Analysis

The Global Stem Cell Therapy Market is Segmented on the basis of Source, Application, End-User, and Geography.

Stem Cell Therapy Market, By Source

Allogeneic Stem Cells:
Stem cells sourced from a donor other than the patient, offering advantages such as off-the-shelf availability and reduced risk of immune rejection.
Autologous Stem Cells:
Stem cells sourced from the patient's own body, minimizing the risk of immune rejection but requiring time for isolation and processing.

Stem Cell Therapy Market, By Application

Oncology:
Stem cell therapy used in cancer treatment, including hematopoietic stem cell transplantation for leukemia and lymphoma, and regenerative therapies for solid tumors.
Orthopedics:
Stem cell therapy applied in orthopedic conditions such as osteoarthritis, joint injuries, and bone fractures, aiming to promote tissue repair and regeneration.
Cardiology:
Stem cell-based therapies targeting cardiovascular diseases such as myocardial infarction, heart failure, and ischemic heart disease, aiming to improve cardiac function and repair damaged tissue.
Neurology:
Stem cell therapies for neurological disorders including Parkinson's disease, Alzheimer's disease, spinal cord injury, and stroke, aiming to promote neural regeneration and functional recovery.
Dermatology:
Stem cell-based treatments for skin conditions such as burns, wounds, and dermatological disorders, aiming to promote tissue healing and regeneration.

Stem Cell Therapy Market, By End-User

Hospitals and Clinics:
Healthcare facilities offering stem cell therapy procedures and regenerative medicine services to patients with various medical conditions.
Research Institutions:
Academic and research institutions conducting preclinical and clinical studies on stem cell therapies, exploring their safety, efficacy, and therapeutic potential.
Biotechnology and Pharmaceutical Companies:
Companies involved in the development, manufacturing, and commercialization of stem cell-based therapies and regenerative medicine products.

Stem Cell Therapy Market, By Geography

North America:
Including the United States and Canada, characterized by advanced healthcare infrastructure, regulatory support, and a robust pipeline of stem cell therapies.
Europe:
Covering regions like the UK, Germany, France, and Italy, witnessing increasing investments in regenerative medicine research and clinical trials.
Asia-Pacific:
Encompassing regions like China, Japan, India, and South Korea, experiencing rapid growth in stem cell research, medical tourism, and healthcare infrastructure development.
Latin America:
Including countries such as Brazil, Mexico, and Argentina, witnessing growing awareness of stem cell therapies and increasing participation in clinical trials.
Middle East and Africa:
Witnessing emerging opportunities in stem cell research, healthcare investment, and adoption of regenerative medicine technologies.
Keyplayers
The major players in the Stem Cell Therapy Market are:
Novartis AG (Switzerland)
Johnson & Johnson (USA)
Roche Holding AG (Switzerland)
Celgene Corporation (USA)
Gilead Sciences, Inc. (USA)
Mesoblast Limited (Australia)
Osiris Therapeutics, Inc. (USA)
Bluebird bio, Inc. (USA)
Editas Medicine, Inc. (USA)
Spark Therapeutics, Inc. (USA)